Houlihan Lokey is pleased to announce that Red Nucleus, a leading provider of strategic services, has been acquired by THL Partners (THL) from The Riverside Company. The transaction closed on October 17, 2024, and the terms of the transaction were not disclosed.
Red Nucleus is an industry-leading integrated provider of learning and development, medical communications, market access, and R&D and clinical solutions to the life sciences industry globally. The company’s comprehensive commercial, medical, and clinical service and software solutions span all stages of the product cycle to help provide lasting value for key stakeholders, including pharmaceutical organizations, HCPs, and patients.
The breadth and depth of Red Nucleus’ services and products have enabled it to become a valuable one-stop-shop and trusted partner for its customers across the entire drug development lifecycle. The company serves more than 200 organizations, including innovative biotech start-ups and the majority of the top 25 global pharmaceutical companies, by market capitalization, helping advance life sciences solutions and improve patient health outcomes globally.
The Riverside Company is a global investment firm focused on being one of the leading private equity and flexible capital options for business owners and portfolio company employees at the smaller end of the middle market by seeking to fuel transformative growth and create lasting value. Since its founding in 1988, Riverside has made more than 1,000 investments. The firm originally invested in Red Nucleus in December 2019.
THL is a premier private equity firm investing in middle-market growth companies exclusively within three sectors: healthcare, financial technology and services, and technology and business solutions. THL couples deep sector expertise through an identified sector opportunity process with dedicated internal operating resources from its strategic resource group to transform and build great companies of lasting value in partnership with management. The firm’s strategic partnership with Red Nucleus will help broaden the company’s suite of commercialization services for its global customer base.
Houlihan Lokey served as financial advisor to Red Nucleus and The Riverside Company. This deal highlights Houlihan Lokey’s leading experience in the pharma commercialization space and represents the firm’s 26th transaction in this sector since 2019.
If you would like more information about Houlihan Lokey or have any questions regarding the firm’s role in this transaction, please contact one of the team members listed below.
| 
